Prostate cancer metastasis in young and middle-aged men

Dmitriy I. Ganov; S. A Varlamov; A. F Lazarev

doi:10.17816/onco40098

Russian Journal of Oncology ›› 2014, Vol. 19 ›› Issue (5) : 28 -30. DOI: 10.17816/onco40098

Articles

research-article

Prostate cancer metastasis in young and middle-aged men

Author information +

History +

PDF

Abstract

For the first time detected prostate cancer in men up to the age of 60 years was identified in 638 patients, accounting for 9.4 percent of all patients with newly diagnosed metastatic prostate cancer before the age of 60 years. prostate cancer first identified before the age of 60 years, 20% of males has a metastatic nature. more than 73% of the patients are aged 54-59 years The localization of metastasis in men with newly diagnosed metastatic prostate cancer before the age of 60 years are the bones of the skeleton, more than 80% lesion is localized in the bones of the pelvis and lumbar spine.

Keywords

metastatic prostate cancer / bone metastasis / age

Cite this article

Download citation ▾

Dmitriy I. Ganov, S. A Varlamov, A. F Lazarev. Prostate cancer metastasis in young and middle-aged men. Russian Journal of Oncology, 2014, 19(5): 28-30 DOI:10.17816/onco40098

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Чиссов В.И., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2011 году. М.; 2012.

[2]	Paulson D.F. Prostate Carcinoma. Philadelphia: Lea & Febiger; 1999.

[3]	Cancel-Tassin G., Latil A., Valeri A., et al. PCAP is the maior known prostate cancer predisposing locus in families from sounth and west Europe. Eur. J. Hum. Genet. 2001; 9(2):135-42.

[4]	Jemal A., Siegel R., Xu J. et al. Cancer statistics, 2010. CA. Cancer. J. Clin. 2010; 60: 277-300.

[5]	Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации. Эксперементальная и клиническая урология. 2011: 2-3.

[6]	Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2005 г. М.: Медицинское информационное агентство; 2006.

[7]	Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann. Oncol. 2005; 16: 481-8.

[8]	Бормотин A.B., Говоров A.B.,Пушкарь Д.Ю. Алгоритм ранней диагностики рака предстательной железы. Русский медицинский журнал. 2003; 8: 13-6.

[9]	Матвеев Б.П., ред. Клиническая онкоурология. М.: 2003.

[10]	Gibbs M. Analysis of chromosome Ig 42.2-43 in 152 families with High risk of prostate cancer. Am. J. Genet. 1999 64; 1087-95.

[11]	Kheirandish P., Chinegwundoh F. Ethnic differences in prostate cancer. Br. J. Cancer. 2011; 105(4): 481-5.

[12]	Берштейн Л.М. Гормональный канцерогенез. СПб.: Наука; 2000.

[13]	Welch H.G., Black W.C. Overdiagnosis in cancer. J. Natl. Cancer. Inst. 2010; 102: 605-13.

[14]	Печерский А.В., Мазаров В.И. и др. Влияние уровня тестостерона на развитие рака предстательной железы. Онкоурология. 2005; 3: 31-8.

[15]	Schroder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 2012; 366: 981-90.

[16]	Русаков И.Г., Алексеев Б.Я. Лечение гормонорефрактерного рака предстательной железы. Современная онкология. 2004; 6: 34-6.

[17]	Leitzmann M.F., Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin. Epidemiol. 2012; (4): 1-11.